Recent research reveals that the cost of semaglutide, the active ingredient in the weight-loss medication Wegovy and the diabetes treatment Ozempic, could be as low as $3 per month, significantly increasing its accessibility. This potential price drop could transform the lives of millions suffering from obesity and diabetes across approximately 160 countries, particularly as patents begin to expire and generic alternatives become available.
A Global Health Crisis
Obesity is a pressing concern globally, with over a billion individuals affected, and the numbers are climbing, especially in low-income countries adopting more Western dietary habits. The World Health Organization (WHO) recognised semaglutide as an essential medicine in September last year, highlighting its importance in combatting this growing health epidemic. However, the high cost of current treatments has been a barrier to access, particularly in poorer nations.
New findings, shared in a pre-print analysis, suggest that semaglutide could be produced for a mere $3 per monthly dose in its injectable form, while oral formulations could be manufactured for around $16. Dr Andrew Hill of Liverpool University’s pharmacology department, a contributor to the study, remarked, “These low prices open the door to worldwide access to an essential medicine.”
Patent Expirations and Global Access
The study highlights that crucial patents on semaglutide will expire this year in ten countries, including Brazil, China, India, South Africa, Turkey, Mexico, and Canada, starting from March 21. This creates an opportunity for generic manufacturers to enter the market. Furthermore, the research indicates that an additional 150 countries have not filed patents for the drug, many of which are in Africa. Together, these nations account for a staggering 69% of individuals with type 2 diabetes and 84% of those living with obesity.
Professor François Venter from Witwatersrand University in Johannesburg emphasised the importance of making these treatments affordable: “Drugs to treat HIV, TB, malaria, and hepatitis are available in low-and-middle-income countries for prices close to production costs. We can replicate this success story for semaglutide.”
The Need for Comprehensive Solutions
While the potential for cheaper treatments is promising, experts caution that simply reducing costs will not resolve the underlying causes of obesity. Dr Nomathemba Chandiwana, chief scientific officer at South Africa’s Desmond Tutu Health Foundation, noted that structural issues such as food insecurity, poverty, and urbanisation must also be addressed. She stated, “This could be very significant for South Africa and many African countries… where cost has been one of the main barriers to access.”
The analysis suggests that about 27% of adults worldwide meet the criteria for medications like semaglutide, with the majority residing in low- and middle-income countries where access remains severely restricted.
Rising Diabetes Rates Demand Urgent Action
Diabetes prevalence has surged dramatically, from 200 million cases in 1990 to an alarming 830 million in 2022, with the most significant increases found in low- and middle-income nations. The link between obesity and numerous health issues, including heart disease, stroke, and cancer, further underscores the urgency for effective treatments. The current global toll of excess weight-related deaths stands at 3.7 million annually.
Despite semaglutide’s promise, it remains prohibitively expensive in wealthier countries, where it is priced at around $200 a month in the United States and £120 in the UK. In contrast, patents in these regions will not expire for another five years, maintaining high costs for those who need it most.
Why it Matters
The findings from this research could herald a significant shift in the treatment landscape for obesity and diabetes, enabling millions in low-income countries to access essential medications. By reducing costs and facilitating the emergence of generic alternatives, there is potential for a healthier global population. However, it is crucial to tackle the systemic issues underlying obesity and diabetes to ensure the long-term effectiveness of these treatments. This multifaceted approach could ultimately lead to improved health outcomes and reduced healthcare burdens worldwide.
